title: Essential thrombocythemia and acute leukemia.
abstract: A case of leukemic evolution from essential thrombocythemia (ET) is described. The patient developed acute myeloid leukemia (AML) six months after diagnosis while receiving hydroxyurea (HU). He died in four days in spite of treatment with low-dose cytarabine (ARA-C).
authors.affiliation: Divisione di Medicina Interna, Ospedale C. Cantù, Abbiategrasso, Milano, Italia.
authors.forename: D
authors.initials: D
authors.lastname: Ferrari
authors.forename: G
authors.initials: G
authors.lastname: Ticozzelli
authors.forename: M
authors.initials: M
authors.lastname: De Vizzi
authors.forename: P
authors.initials: P
authors.lastname: Corigliano
authors.forename: G
authors.initials: G
authors.lastname: De Vizzi
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D002471:Cell Transformation, Neoplastic; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000473:pathology*; D008297:Male; D013920:Thrombocythemia, Essential / Q000188:drug therapy / Q000473:pathology*
chemical_list: D006918:Hydroxyurea